OSAKA, Japan & SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Santen Pharmaceutical Co., Ltd. (“Santen” TSE: 4536) and Glaukos Corporation (“Glaukos” NYSE: GKOS), announced today that Santen’s U.S. subsidiary, Santen Inc., has entered into a multi-year agreement whereby Glaukos will become the exclusive distributor of the MicroShunt (development code: DE-128) solely in the U.S. market. The MicroShunt is a novel, minimally-invasive, ab-externo surgical device being developed for primary open-angle glauc

Source link